MiR-362-3p enhances platinum response in breast cancer
Presenter: Gerburg Wulf, MD, PhD Session: Translational Biomarkers and Emerging Molecular Approaches Time: 4/22/2026 9:00:00 AM → 4/22/2026 12:00:00 PM
Authors
Zhaoji Liu 1 , Shizhong Ke 1 , Xiaohui Li 1 , Catherine Wu 1 , Madison M. Uyemura 1 , Brian R. Sardella 1 , Erica S. Massicott 1 , Lin Wang 1 , Emily K. Aronson 1 , Dimitra Karagkouni 1 , Nikolas Kalavros 1 , Ioannis S. Vlachos 1 , Felipe Batalini 2 , Cristina S. Bogsan 1 , Jit Kong Cheong 3 , Lihan Zhou 3 , He Cheng 3 , Phillip Munson 3 , Erica L. Mayer 4 , Judy E. Garber 4 , Stuart J. Schnitt 1 , Nadine M. Tung 1 , Andrea L. Kasinski 5 , Frank J. Slack 1 , Gerburg M. Wulf 1 , Yujing J. Heng 1 1 Beth Israel Deaconess Medical Center, Boston, MA, 2 Mayo Clinic, Phoenix, AZ, 3 Mirxes, Singapore, Singapore, 4 Dana Farber Cancer Institute, Boston, MA, 5 Purdue University, West Lafayette, IN
Abstract
The INFORM trial (NCT01670500) was a randomized, two-arm Phase II neoadjuvant study comparing the efficacy of a platinum-based regimen (cisplatin) versus an anthracycline (AC)-based regimen in participants with germline BRCA1/2 mutations and early-stage, HER2-negative breast cancer. MicroRNAs (miRNAs) are emerging as promising non-invasive biomarkers for disease detection and treatment monitoring. The initial aim of this study was to evaluate whether pretreatment plasma miRNA profiles were associated with treatment outcomes in the INFORM trial cohort. Pretreatment plasma samples from 97 INFORM participants ( n =53 cisplatin and n =44 AC) were screened for 352 miRNAs commonly implicated in cancer using the qPCR-based ID3EAL TM Cancer Panel. Twenty out of 53 participants achieved residual cancer burden (RCB) score of 0 or 1 with cisplatin and 20/44 with AC. Higher plasma miR-362-3p expression was associated with a favorable response to cisplatin (1.7-fold; p n =79) did not significantly correlate with plasma expression and was not associated with RCB 0/1 ( p >0.05). In TCGA, miR-362-3p expression was higher in breast tumors than in adjacent normal tissue, and higher in triple negative breast cancers (TNBCs) compared with hormone receptor-positive tumors (both FDR BRCA mutation or Single Base Substitution Signature 3 (SBS3) status. The miR-362-3p findings in INFORM did not replicate in a sister trial, TBCRC 030 (NCT01982448; 11 out of 46 cisplatin-treated patients achieved RCB 0/1, p =0.46). These results suggest that while miR-362-3p is unsuitable as a circulating biomarker for cisplatin response, it may play an important biological role in mediating cisplatin sensitivity in TNBCs, independent of BRCA1/2 mutations. Functional studies demonstrated that miR-362-3p is expressed and secreted by TNBC cell lines, operates as a tumor suppressor, and generally correlates with cisplatin sensitivity. Overexpression of miR-362-3p rendered MDA-MB-231 and CAL-51 cells cisplatin sensitive, while knockdown induced resistance in MDA-MB-436 cells. Ongoing studies are testing whether these effects translate in xenograft models. In silico and functional assays identified BCLAF1, a DNA damage response (DDR) regulator, as a direct target of miR-362-3p. Overexpression of miR-362-3p suppresses BCLAF1 mRNA and protein levels. Our findings demonstrate that miR-362-3p enhances cisplatin responsiveness by targeting BCLAF1 . A miR-362-3p-based therapeutic may be useful as a co-agent to enhance tumor responses to platinum-based chemotherapy.
Disclosure
Z. Liu, None.. S. Ke, None.. X. Li, None.. C. Wu, None.. M. M. Uyemura, None.. B. R. Sardella, None.. E. S. Massicott, None.. L. Wang, None.. E. K. Aronson, None.. D. Karagkouni, None.. N. Kalavros, None.. I. S. Vlachos, None.. F. Batalini, None.. C. S. Bogsan, None.. J. Cheong, None.. L. Zhou, None.. H. Cheng, None.. P. Munson, None.. E. L. Mayer, None.. J. E. Garber, None.. S. J. Schnitt, None.. N. M. Tung, None.. A. L. Kasinski, None.. F. J. Slack, None.. G. M. Wulf, None.. Y. J. Heng, None.
Cited in
Control: 546 · Presentation Id: 8546 · Meeting 21436